Serum anti-myomeglin antibodies is a useful tumor marker to detect gastrointestinal cancer

为了寻找新的食管鳞癌(SCC)血清标志物，我们用重组基因表达克隆(SEREX)技术进行了抗原的血清学鉴定。用从食道癌细胞系T.Tn中提取的λZAPII噬菌体文库感染大肠杆菌，筛选其与食管鳞癌患者同种异体血清中抗体的相互作用。我们确定myomegalin(磷酸二酯酶4D相互作用蛋白/PDE4DIP)是一种新的食管鳞癌的Serex抗原。免疫印迹分析显示，91例患者中有43例(47%)血清中存在抗肌红蛋白抗体(S-肌红蛋白抗体)，而在45例健康对照组中仅有1例(2.2%)。抗肌钙蛋白抗体在I期患者中占38%。在其他常规肿瘤标志物中，S-肌红蛋白抗体的阳性率最高。尽管S肌红蛋白抗体的存在与患者的任何临床病理特征无关，但多因素分析显示S肌红蛋白抗体的存在与预后良好显著相关。

In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was infected with λZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blotting analysis revealed that serum anti-myomegalin antibodies (s-myomegalin-Abs) were present in 43 out of 91 (47%) patients but in only one out of 45 (2.2%) healthy controls. Anti-myomegalin Abs were present 38% of stage I patients. The positive rate of s-myomegalin-Abs was the highest among the other conventional tumor markers. Although the presence of s-myomegalin-Abs was not related to any of clinicopathological features of the patients concerned, multivariate analysis indicated that presence of s-myomegalin-Abs was significantly associated with favorable prognosis